StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Lifecore Biomedical Files Merger Proxy; $6.28 Cash Plus CVR per Share

Lifecore Biomedical filed a definitive proxy for a Dec. 23, 2026 special meeting where stockholders will vote on a $6.28-per-share cash merger with a Webster Equity Partners affiliate, plus one contingent value right per share.

What happened

Lifecore Biomedical, Inc. filed a definitive proxy statement (Form DEFM14A) on November 13, 2026, for a special meeting of stockholders to be held virtually on December 23, 2026 at 10:00 a.m. Central Time.

Stockholders are being asked to vote on a merger agreement the company entered into on September 27, 2026 with Lifecore Inc. and Hazel Merger Sub, Inc. Both are affiliates of Webster Equity Partners, according to the filing.

Under the deal, Merger Sub would merge into Lifecore, with Lifecore surviving as a wholly owned subsidiary of Lifecore Inc. Each outstanding share of common stock would be converted into the right to receive $6.28 in cash, without interest, plus one contingent value right (CVR) per share, per the proxy.

What the company does

Lifecore Biomedical is a Chaska, Minnesota-based company. It files with the SEC under the classification 'Pharmaceutical Preparations.' The excerpted proxy text does not describe its product lines or operating business in detail; that description appears later in the full document, which is not included in the excerpt reviewed here.

The vote and the terms

The special meeting will cover three proposals: adopting the merger agreement, an advisory (non-binding) vote on executive compensation tied to the merger, and approval of any adjournment to solicit more proxies. The board unanimously recommends voting for all three.

Approval of the merger agreement requires the affirmative vote of holders of a majority of the combined voting power of outstanding common stock and Series A Convertible Preferred Stock, voting together as a single class. The Series A votes on an as-converted basis. The record date was November 4, 2026.

The filing states that failing to vote, or abstaining, has the same effect as a vote against the merger agreement. The proxy notes that brokers cannot vote shares held in street name on the proposals without instructions from the holder.

What this means

A DEFM14A is the definitive version of a merger proxy statement. A company files a preliminary proxy first (which may be reviewed by the SEC), then a definitive one, which is the version actually mailed to shareholders. 'Definitive' means the document is final and can be used to solicit votes. It satisfies the company's obligation under Section 14(a) of the Securities Exchange Act to give shareholders full disclosure before they vote on a major transaction.

The consideration here is not simple cash. Common holders get $6.28 per share plus a contingent value right. A CVR is a tradable right to receive an additional payment later if specified milestones are met; if they are not, the CVR can expire worthless. The proxy excerpt does not state what those milestones are — they are set out in a CVR agreement attached as Exhibit C to the merger agreement, which is referenced but not included in the text reviewed.

Holders of the Series A Convertible Preferred Stock receive a different amount: cash equal to the 'Conversion Amount' defined in the company's certificate of designations, plus one CVR for each common share the preferred would convert into. Preferred stock is a class of equity that ranks ahead of common stock and typically carries conversion rights; here, the filing states the Conversion Amount equalled $6.53 per share of common stock as of September 27, 2026, slightly above the $6.28 common price, reflecting the preferred's senior position.

Because the merger is a cash deal at a fixed price, the stock's trading price around $6.42 on the event date — as against the $6.28 cash component — reflects, at least in part, the market's separate valuation of the CVR, which the filing does not quantify.

If the merger agreement proposal is approved and the other conditions are met, the merger would close and Lifecore would become a private subsidiary of a Webster Equity Partners affiliate; its common stock would no longer trade publicly. The filing does not state a projected closing date beyond the December 23, 2026 meeting.

The advisory compensation proposal is a 'say-on-golden-parachute' vote required by SEC rules when a merger triggers change-in-control payments to executives. It is non-binding, meaning a 'no' vote does not block the merger.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.